


## CLAIMS

1. A compound of the formula:



5 wherein

ring A represents an aromatic ring optionally having substituents;

B, Y and Ya are the same or different and each represents a bond or a spacer having a main chain of 1 to 6 atoms;

10  $R^1$  and  $R^2$  are the same or different and each represents a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, or  $R^1$  and  $R^2$ , together with the adjacent nitrogen atom, form a nitrogen-containing heterocyclic ring  
 15 optionally having substituents, or  $R^1$  is linked with ring A together with the adjacent nitrogen atom and B to form a 5- to 7-membered nitrogen-containing heterocyclic ring;

$R^3$  represents a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having  
 20 substituents;

$R^4$  and  $R^5$  are the same or different and each represents a hydrogen atom or a hydrocarbon group optionally having substituents, or  $R^4$  and  $R^5$ , together with the adjacent carbon atom, form a ring optionally having substituents;

25  $R^6$  represents an indolyl group optionally having substituents; and

Z and Za are the same or different and each represents a

hydrogen atom, a halogen atom or a cyclic group optionally having substituents; or a salt thereof.

2. A prodrug of the compound according to claim 1 or a salt thereof.

3. The compound according to claim 1, wherein  $R^3$  is a hydrogen atom or a  $C_{1-6}$  alkyl optionally having substituents.

4. The compound according to claim 1, wherein one of  $R^4$  and  $R^5$  is a hydrogen atom, and the other is a  $C_{1-6}$  alkyl optionally having substituents.

5. The compound according to claim 1, wherein Z is a cyclic group optionally having substituents.

6. The compound according to claim 5, wherein the cyclic group is piperidinyl or piperazinyl.

7. The compound according to claim 5, wherein Z is piperidinyl or piperazinyl, each of which is substituted by a group of the formula: -Yd-Ara wherein Yd represents a bond or a spacer having a main chain of 1 to 6 atoms, and Ara represents a monocyclic group optionally having substituents.

8. The compound according to claim 1, wherein Ya is a bond, and Za is a hydrogen atom.

9. The compound according to claim 1, wherein B is a  $C_{1-6}$  alkylene.

10. The compound according to claim 1, wherein the aromatic ring represented by ring A is benzene.

11. The compound according to claim 1, wherein R<sup>1</sup> and R<sup>2</sup> are C<sub>1-6</sub> alkyl.
12. The compound according to claim 1, wherein Y is -CO-.
13. The compound according to claim 1, which is  
N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-  
(methylamino)carbonyl)phenyl)amino)carbonyl)-2-(1H-indol-3-  
10 yl)propyl)-4-(2-methylphenyl)-1-piperidinecarboxamide;  
N-((1R,2S)-1-(((2-((dimethylamino)carbonyl)-5-  
(dimethylamino)methyl)phenyl)amino)carbonyl)-2-(1H-indol-3-  
yl)propyl)-4-(4-fluorophenyl)-1-piperidinecarboxamide;  
N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-  
15 methoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-  
fluoro-2-methylphenyl)-3-oxo-1-piperazinecarboxamide;  
N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-  
methoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(2-  
methylphenyl)-1-piperazinecarboxamide;  
20 N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-  
ethoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-  
fluorophenyl)-1-piperazinecarboxamide; or  
N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-  
ethoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-  
25 phenyl)-1-piperidinecarboxamide.
14. A pharmaceutical preparation comprising the compound according to claim 1, a salt thereof or a prodrug thereof.
15. The pharmaceutical preparation according to claim 14, which is a somatostatin receptor binding inhibitor.
16. The pharmaceutical preparation according to claim 15,

which is a somatostatin subtype 2 receptor binding inhibitor.

17. The pharmaceutical preparation according to claim 14,  
which is a somatostatin receptor agonist.

5

18. The pharmaceutical preparation according to claim 17,  
which is a somatostatin subtype 2 receptor agonist.

19. The pharmaceutical preparation according to claim 14,  
10 which is a prophylactic or therapeutic agent for diabetes or  
diabetic complications.

20. The pharmaceutical preparation according to claim 14,  
which is a prophylactic or therapeutic agent for obesity.

15


21. Use of the compound according to claim 1, a salt thereof  
or a prodrug thereof for manufacturing a somatostatin receptor  
binding inhibitor.

20 22. A method for inhibiting somatostatin receptor binding in a  
mammal, which comprises administering to the mammal an  
effective amount of the compound according to claim 1, a salt  
thereof or a prodrug thereof.

25 23. Use of the compound according to claim 1, a salt thereof  
or a prodrug thereof for manufacturing a prophylactic or  
therapeutic agent for diabetes or diabetic complications.

24. A method for preventing or treating diabetes or diabetic  
30 complications in a mammal, which comprises administering to  
the mammal an effective amount of the compound according to  
claim 1, a salt thereof or a prodrug thereof.

25. Use of the compound according to claim 1, a salt thereof or a prodrug thereof for manufacturing a prophylactic or therapeutic agent for obesity.
- 5 26. A method for preventing or treating obesity in a mammal, which comprises administering to the mammal an effective amount of the compound according to claim 1, a salt thereof or a prodrug thereof.
- 10 27. A method for producing a compound of claim 1 or a salt thereof, which comprises reacting a compound of the formula:




wherein

Y represents a bond or a spacer having a main chain of 1 to 6  
15 atoms;

R<sup>4</sup> and R<sup>5</sup> are the same or different, and each represents a hydrogen atom or a hydrocarbon group optionally having substituents, or R<sup>4</sup> and R<sup>5</sup>, together with the adjacent carbon atom, form a ring optionally having substituents;

20 R<sup>6</sup> represents an indolyl group optionally having substituents; Z represents a hydrogen atom, a halogen atom or a cyclic group optionally having substituents; or a salt thereof, with a compound of the formula:




25 wherein

ring A represents an aromatic ring optionally having substituents;

B represents a bond or a spacer having a main chain of 1 to 6 atoms;

5  $R^1$  and  $R^2$  are the same or different, and each represents a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, or  $R^1$  and  $R^2$ , together with the adjacent nitrogen atom, form a nitrogen-containing heterocyclic ring  
 10 optionally having substituents, or  $R^1$  is linked with ring A together with the adjacent nitrogen atom and B to form a 5- to 7-membered nitrogen-containing heterocyclic ring;


$R^3$  represents a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having  
 15 substituents; or a salt thereof to give a compound of the formula:



wherein

each symbol is as defined above; or a salt thereof, and  
 20 optionally reacting the compound or a salt thereof with a compound of the formula:  $L^4$ -Ya-Za wherein  $L^4$  represents a leaving group; Ya represents a bond or a spacer having a main chain of 1 to 6 atoms; Za represents a hydrogen atom, a halogen atom or a cyclic group optionally having substituents;  
 25 or a salt thereof.

28. A compound of the formula:



wherein

Y represents a bond or a spacer having a main chain of 1 to 6 atoms;

5 R<sup>4</sup> and R<sup>5</sup> are the same or different, and each represents a hydrogen atom or a hydrocarbon group optionally having substituents, or R<sup>4</sup> and R<sup>5</sup>, together with the adjacent carbon atom, form a ring optionally having substituents;

R<sup>6</sup> represents an indolyl group optionally having substituents;

10 Zb represents piperidinyl or piperazinyl, each of which is substituted by a group of the formula: -Yd-Ara wherein Yd represents a bond or a spacer having a main chain of 1 to 6 atoms, and Ara represents a monocyclic group optionally having substituents; or a salt thereof.

15